NAMS — NewAmsterdam Pharma Co N.V.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1936258 ·
Last close
$19.39
Market Cap
$2.33B
52W High
$42.21
52W Low
$17.90
ADV30
1,644,199
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 19,164,000 — -44,188,000 -17,389,000 687,985,000 423,129,000 57,203,000
Jun 2026 3,701,000 — -64,864,000 -64,135,000 704,452,000 424,151,000 73,030,000
Mar 2026 3,040,000 — -58,420,000 -48,441,000 732,643,000 457,607,000 67,421,000
Dec 2025 32,000 — -65,980,000 -74,923,000 769,284,000 490,002,000 85,853,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-150,466,000
Investing CF
$-3,713,000
Financing CF
$41,241,000
CapEx
$-395,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.67
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-892,355,000
Inventory
—
Receivables
$26,995,000
ST Investments
$205,113,000
EBIT TTM
$-233,452,000
Pretax Income TTM
$-203,681,000
Interest Exp TTM
—
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,121,000
EBITDA
$-244,163,008
Free Cash Flow
$-45,358,376
Enterprise Value
$1,868,140,928
Total Cash
$633,854,016
Total Debt
$82,000
Shares Out
119,929,998
Trailing EPS
$-1.69
Book Value
$5.97
ROE
-36.8%
ROA
-20.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 22,503,000 -225,683,000 -203,819,000 769,284,000 85,853,000 683,431,000 -147,783,000
Dec 2024 45,563,000 -176,289,000 -241,598,000 864,620,000 107,120,000 757,500,000 -158,564,000
Dec 2023 14,090,000 -182,967,000 -176,937,000 347,097,000 58,704,000 288,393,000 -141,218,000
Dec 2022 102,694,000 -3,557,000 -22,634,000 478,497,000 48,431,000 430,066,000 10,665,000

TTM Snapshot

Revenues TTM
$7,121,000
NetIncome TTM
$-259,504,000
OpCashFlow TTM
—
Assets (Latest)
$704,452,000
Forward EPS
$-1.76

Max Pain — expiry 2027-01-15

max pain strike: $25.00 · spot: $19.74 · call oi: 3,913 · put oi: 12,444
Expected Move to 2027-01-15: ±$5.47 (27.74%) — implied range $14.26 – $25.21 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GLPGF Lakefront Biotherapeutics NV $2.30B $35.15 —
RCUS Arcus Biosciences, Inc. $2.36B $16.39 —
PBH Prestige Consumer Healthcare Inc. $2.29B $48.22 —
PHVS Pharvaris N.V. $2.27B $32.28 —
LKFT Lakefront Biotherapeutics NV $2.25B $34.39 —

News headlines (Yahoo Finance, 1h cache)

The Billionaire-Backed Pharma Play Sitting on a $640M Cash Pile at 52-Week Lows
2026-11-07 23:26 · Yahoo
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 12:55 · Yahoo
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
2026-11-04 12:30 · Yahoo
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
2026-11-03 13:00 · Yahoo
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
2026-10-13 23:22 · Yahoo
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:01 · Yahoo
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
2026-09-29 12:00 · Yahoo
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
2026-09-23 01:20 · Yahoo
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
2026-09-21 13:00 · Yahoo
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
2026-09-20 04:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.